Back to search

Article

HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapy

2018-09-09

Abstract excerpt

<h4>Summary</h4> <h4>Background</h4> Anti-tumour necrosis factor (anti-TNF) therapies are the most widely used biologic therapies for treating immune-mediated diseases. Their efficacy is significantly reduced by the development of anti-drug antibodies which can lead to treatment failure and adverse reactions. The biological mechanisms underlying antibody development are unknown but the ability to identify subjec...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
6b749965-eb71-5ea2-9478-6a1720b5815c
DOI
10.1101/410035
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapyDOI 10.1101/410035
Clinical utility of pre-treatment four-digit-resolution HLA genotyping to guide anti-tumor necrosis factor choice and concomitant immunomodulator use.Semantic proximity
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases.Semantic proximity
Molecular Insight into the Role of HLA Genotypes in Immunogenicity and Secondary Refractoriness to Anti-TNF Therapy in IBD PatientsSemantic proximity
Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study.Semantic proximity
Impact of HLA-DQA1*05 Genotype in Immunogenicity and Failure to Treatment with Tumour Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.Semantic proximity
HLA-DQA1*05 Carriage is Associated with treatment failure and the induction of anti-IFX antibodies in IBD patientsSemantic proximity
HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease.Semantic proximity
Identification of HLA-DRB1 association to adalimumab immunogenicity.Semantic proximity
Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and InfliximabSemantic proximity
Association between genetic variants and development of antibodies to infliximab: A cross-sectional study in Chinese patients with Crohn’s diseaseSemantic proximity
Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients.Semantic proximity
HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis.Semantic proximity
Select a neighboring publication to make it the new centre.